Frontiers | Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes
1 Department of Lymphoma/Myeloma, The University of Texas at MD Anderson Cancer Center, Houston, TX, United States 2 Department of Hematology, West China Hospital, Sichuan University, Chengdu, China 3 Cellenkos Inc., Houston, TX, United States 4 Department of Microbial Pathogenesis & Immunology, Texas A & M University, Bryan, TX, Uni ted States Background: Adoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs
